How can the Pharma How can the Pharma Industry assist the NHS Industry assist the NHS in constrained times? in constrained times? Can Pharma help with Can Pharma help with QIPP? QIPP? PDIG meeting, 10 June 2010 Alison Clough Commercial & Communications Director, Association of the British Pharmaceutical Industry
18
Embed
How can the Pharma Industry assist the NHS in constrained times? Can Pharma help with QIPP? PDIG meeting, 10 June 2010 Alison Clough Commercial & Communications.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
How can the Pharma Industry How can the Pharma Industry assist the NHS in constrained assist the NHS in constrained
times? times? Can Pharma help with QIPP? Can Pharma help with QIPP?
PDIG meeting, 10 June 2010
Alison CloughCommercial & Communications Director, Association of the
British Pharmaceutical Industry
The environment is getting tougher
Ageing demographic
Increasing demand on healthcare resources
Economic slowdown
Acceleration of technical advancement
Win- win-win
Partners in Improving Care and Healthcare Delivery
Through the continued process of innovation in the UK, further benefits can
•1 in 5 of the leading medicines used around the world were developed by a UK Company
• Increase in life expectancy over time
Prescription for innovation (ABPI 2009); WHO (2006)
November 2009
Innovation fuels better patient outcomes
Coronary heart diseaseAge standardised mortality rates in population
aged 15-74, circa 2005
0
20
40
60
80
100
120
140
OHE calculation based on WHO Mortality Database (WHO), Mortality Statistics Series DH2 (ONS), Mortality Statistics Deaths Registered DR_06 (ONS), Vital Events Reference Tables (General Register Office of Scotland), Demographic Statistics (Northern Ireland Statistics and Research Agency), Population Estimates and Projections (ONS).
Mortality rates from disease remain high - there remains scope for further improvement in public health
Heart and circulatorydisorders –leadingcause of death inEngland in 2007,resulting in 158 500deaths (34% of alldeaths)
Cancer responsible for23% of all deaths
Atlas of Risk (NHS 2009) Slide reproduced courtesy of Pfizer
34%
23%
Medicines Life Cycle in UK ...delivering efficiencies but out of balance ...?
The UK has amongst the lowest market share of new medicines across
Europe
UK has slow & low use of innovative
medicines
Source: Compendium of Health Statistics 2009 (OHE), updated Hospital prescribing data (IC) PPA and PCA data. Market Statistics IMS World Review, OECD GDP data. PPRS reports to Parliament 6th and 10th IMS world review EGA National Association 2007.
Encourage Innovation
Comparatively, UK has low new product uptake
Source: IMS world review
Medicines Life Cycle in UK ...delivering efficiencies but out of balance ...?
The UK has amongst the lowest market share of new medicines across
Europe
3 price cuts since 2005
UK has slow & low use of innovative
medicines
UK prices are amongst the
lowest in Europe
Source: Compendium of Health Statistics 2009 (OHE), updated Hospital prescribing data (IC) PPA and PCA data. Market Statistics IMS World Review, OECD GDP data. PPRS reports to Parliament 6th and 10th IMS world review EGA National Association 2007.
Maximise value for patient,
NHS & Industry
Encourage Innovation
UK prices lowest in official PPRS Report to Parliament-December 2009
Table: price index for top 150 UK branded medicines (UK = 100) Bilateral comparisons of ex-manufacturer prices (sources PPRS reports to Parliament 6 th and 10th)
Medicines Life Cycle in UK ...delivering efficiencies but out of balance ...?
The UK has amongst the lowest market share of new medicines across
Europe
3 price cuts since 2005
• 83% generic prescribing• 65% by volume is generics•Average price of generics amongst lowest in Europe
UK has slow & low use of innovative
medicines
UK prices are amongst the
lowest in EuropeUK has very
efficient use of generics
Source: Compendium of Health Statistics 2009 (OHE), updated Hospital prescribing data (IC) PPA and PCA data. Market Statistics IMS World Review, OECD GDP data. PPRS reports to Parliament 6th and 10th IMS world review EGA National Association 2007.
Maximise value for patient,
NHS & Industry
EfficiencyEncourage Innovation
The UK is amongst the EU markets with largest penetration of
generics, with ~65% of volume
Source: EGA National Association 2007
Generics market share in Europe (2006)
Generics share of volumes (%)
Generics share of value (%)
2009 UK generic prescribing rate =83%
Medicines Life Cycle in UK ...delivering efficiencies but out of balance ...?
The UK has amongst the lowest market share of new medicines across
Europe
3price cuts since 2005
• 83% generic prescribing• 65% by volume is generics• Average price of generics
amongst lowest in Europe
UK has slow & low use of innovative
medicines
UK prices are amongst the
lowest in EuropeUK has very
efficient use of generics
Source: Compendium of Health Statistics 2009 (OHE), updated Hospital prescribing data (IC) PPA and PCA data. Market Statistics IMS World Review, OECD GDP data. PPRS reports to Parliament 6th and 10th IMS world review EGA National Association 2007.
Maximise value for patient,
NHS & Industry
EfficiencyEncourage Innovation
Only 1% GDP is spent on medicines in UK cf EU average 1.5%, Fr 2%, Greece 2.3%
Source: Compendium of Health Statistics 2009 (OHE), updated Hospital prescribing data (IC) PPA and PCA data
%
NHS spend and Medicines Bill as a percentage of the NHS costs 1998-2008
Total Medicines Bill as a % of NHS spend has been in sustained decline since 2004
Annu
al S
pend
(£bi
llion
)
Economic picture
• The medicines bill is already delivering efficiencies and is under control.
• Important to meet NHS / health needs as well as economic /industrial policy.
• Pharma is one of the key industries underpinning economic recovery.
Driving health & economic benefit for the UK
Opportunities for industry participation in QIPP
• Joint working - implement national strategies for long term conditions or tackle local priorities
– Many examples contained within the ABPI/DH ‘Moving Beyond Sponsorship’ Toolkit.
• Support for the redesign of care pathways - ensure the appropriate use of innovative new medicines.
• Management support to review processes & support change programmes.
Happy Hearts Project
Aim- to find and treat ‘hard to reach’ patients with multiple CVD risk factors and improve patient care and services in Nottingham.
• Nottingham City PCT and six companies with ABPI• Primary care based CVD risk identification and management• Nottingham mortality rates significantly higher than the
national average. • Targeted at 13 GP practices in most deprived areas
Identified 1352 patients (66%) with a risk level of >20%. Patients were given support to manage and reduce that risk including appropriate medication.
Partners in Improving Care and Healthcare Delivery